

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 581426982 US (box 1) and EV 581426996 US (box 2), in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 18, 2007

Signature:

Rosemarie Pulje-Salmeron
(Rosemarie Pulje-Salmeron)

Patent
Docket No. 514712001600



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inter Patent Application of:
David L. SHELTON

Serial No.: 10/549,441

International Filing Date: March 22, 2004

For: METHODS FOR TREATING TAXOL-
INDUCED GUT DISORDER

Examiner: R. Schwadron

Group Art Unit: 1644

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

05/22/2007 CCHAU1 00000022 031952 10549441
02 FC:1806 180.00 DA

- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of ___ is enclosed.
- ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other


Application Serial No. 10/549,441

Patent
Docket No. 514712001600


fees due in connection with the filing of this document to **Deposit Account No. 03-1952**
referencing 514712001600.

Dated: May 18, 2007

Respectfully submitted,

By 
Jie Zhou

Registration No.: 52,395
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5922



ALTERNATIVE TO PTO/SB/08A/B (09/06)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/549,441
				Filing Date	(Intl.) March 22, 2004
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	1	of	10	Attorney Docket Number	514712001600

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document.	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2002/0065259-A1	05-30-2002	Schatzberg et al.	
	2.	US-2004/0137513-A1	07-15-2004	Devaux et al.	
	3.	US-2005/0089521-A1	04-28-2005	Shelton	
	4.	US-2007/0031418-A1	02-08-2007	Tabares et al.	
	5.	US-4,676,980	06-30-1987	Segal et al.	
	6.	US-4,777,127	10-11-1988	Suni et al.	
	7.	US-4,816,567	03-28-1989	Cabilly et al.	
	8.	US-5,219,740-A	06-15-1993	Miller et al.	
	9.	US-5,422,120-A	06-06-1995	Kim	
	10.	US-5,500,362-A	03-19-1996	Robinson et al.	
	11.	US-5,530,101-A	06-25-1996	Queen et al.	
	12.	US-5,545,806-A	08-13-1996	Lonberg et al.	
	13.	US-5,545,807-A	08-13-1996	Surani et al.	
	14.	US-5,565,332-A	10-15-1996	Hoogenboom et al.	
	15.	US-5,569,825-A	10-29-1996	Lonberg et al.	
	16.	US-5,580,717-A	12-03-1996	Dower et al.	
	17.	US-5,580,859-A	12-03-1996	Felgner et al.	
	18.	US-5,585,089-A	12-17-1996	Queen et al.	
	19.	US-5,604,202-A	02-18-1997	Kessler et al.	
	20.	US-5,625,126-A	04-29-1997	Lonberg et al.	
	21.	US-5,633,425-A	05-27-1997	Lonberg et al.	
	22.	US-5,661,016-A	08-26-1997	Lonberg et al.	
	23.	US-5,693,761-A	12-02-1997	Queen et al.	
	24.	US-5,693,762-A	12-02-1997	Queen et al.	
	25.	US-5,733,743-A	03-31-1998	Johnson et al.	
	26.	US-5,750,373-A	05-12-1998	Garrard et al.	
	27.	US-5,766,863-A	06-16-1998	Godowski et al.	
	28.	US-5,807,715-A	09-15-1998	Morrison et al.	
	29.	US-5,814,482-A	09-29-1998	Dubensky, Jr. et al.	
	30.	US-5,821,337-A	10-13-1998	Carter et al.	
	31.	US-5,866,692-A	02-02-1999	Shitara et al.	
	32.	US-5,891,650-A	04-06-1999	Godowski et al.	
	33.	US-5,910,574-A	06-08-1999	Presta et al.	
	34.	US-5,997,867-A	12-07-1999	Waldmann et al.	
	35.	US-6,054,297-A	04-25-2000	Carter et al.	
	36.	US-6,180,370-B1	01-30-2001	Queen et al.	
	37.	US-6,180,377-B1	01-30-2001	Morgan et al.	
	38.	US-6,184,217-B1	02-06-2001	Engber et al.	
	39.	US-6,210,671-B1	04-03-2001	Co	
	40.	US-6,265,150-B1	07-24-2001	Terstappen et al.	
	41.	US-6,331,415-B1	12-18-2001	Cabilly et al.	
	42.	US-6,350,861-B1	02-26-2002	Co et al.	
	43.	US-6,376,471-B1	04-23-2002	Lawrence, III et al.	
	44.	US-6,413,942-B1	07-02-2002	Felgner et al.	
	45.	US-6,436,908-B1	08-20-2002	Koch et al.	
	46.	US-6,548,640-B1	04-15-2003	Winter	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 1135398

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/549,441
				Filing Date	(Intl.) March 22, 2004
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	2	of	10	Attorney Docket Number	514712001600

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	47.	EP-0 345 242-A2, A3	12-06-1989	Smithkline Biologicals S.A.		
	48.	EP-0 519 596-A1, B1	02-23-2005	Merck & Co. Inc. et al.		
	49.	EP-0 524 968-A1, A4, B1	02-03-1993	Depotech Corporation		
	50.	GB-2,200,651-A	08-10-1988	Al-Sumidaie		
	51.	WO-87/04462-A1	07-30-1987	Cell Tech Limited et al.		
	52.	WO-90/07936-A1	07-26-1990	Chiron Corporation		
	53.	WO-90/11092-A1	10-04-1990	Vical, Inc. et al.		
	54.	WO-91/00360-A1	01-10-1991	Medarex, Inc.		
	55.	WO-91/02805-A2, A3	03-07-1991	Viagene, Inc.		
	56.	WO-91/14445-A1	10-03-1991	Research Development Foundation		
	57.	WO-92/20373-A1	11-26-1992	Repligen Corporation		
	58.	WO-93/03769-A1	03-04-1993	United States of America represented by The Secretary, Department of Health and Human Services		
	59.	WO-93/06213-A1	04-01-1993	Medical Research Council et al.		
	60.	WO-93/10218-A1	05-27-1993	United States Government as represented by the Secretary of the Department of Health and Human Services		
	61.	WO-93/11230-A1	06-10-1993	Dynal AS		
	62.	WO-93/19191-A1	09-30-1993	Centre National de la Recherche Scientifique et al.		
	63.	WO-93/25234-A1	12-23-1993	The Regents of the University of California		
	64.	WO-93/25698-A1	12-23-1993	United States Government as represented by the Secretary of the Department of Health and Human Services		
	65.	WO-94/03622-A1	02-17-1994	Imperial College of Science Technology & Medicine		
	66.	WO-94/04690-A1	03-03-1994	Genentech, Inc.		
	67.	WO-94/12649-A2, A3	06-09-1994	Genzyme Corporation		
	68.	WO-94/23697-A1	10-27-1994	Depotech Corporation		
	69.	WO-94/28938-A1	12-22-1994	The Regents of the University of Michigan		
	70.	WO-95/00655-A1	01-05-1995	McMaster University		
	71.	WO-95/07994-A2, A3	03-23-1995	Viagene, Inc.		
	72.	WO-95/11984-A2, A3	05-04-1995	Canji, Inc.		
	73.	WO-95/13796-A1	05-26-1995	Depotech Corporation		
	74.	WO-95/30763-A2, A3	11-16-1995	Viagene, Inc.		
	75.	WO-96/17072-A2, A3	06-06-1996	Chiron Viagene, Inc.		
	76.	WO-97/42338-A1	11-13-1997	Chiron Viagene, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/549,441
				Filing Date	(Intl.) March 22, 2004
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	3	of	10	Attorney Docket Number	514712001600

77.	WO-98/49308-A1	11-05-1998	Genentech, Inc.		
78.	WO-99/58572-A1	11-18-1999	Cambridge University Tech. Services, Limited		
79.	WO-00/41719-A1	07-20-2000	Regeneron Pharmaceuticals, Inc.		
80.	WO-01/27160-A1	04-19-2001	Applied Molecular Evolution, Inc.		
81.	WO-2004/058184-A2, A3	07-15-2004	Rinat Neuroscience Corp.		
82.	WO-2004/058190-A2, A3	07-15-2004	Rinat Neuroscience Corp.		
83.	WO-2004/084836-A2, A3	10-07-2004	Rinat Neuroscience Corp.		
84.	WO-2006/116609-A2, A3	11-02-2006	Rinat Neuroscience Corp.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	85.	Al-Lazikani, B. et al. (1997). "Standard Conformations for the Canonical Structures of Immunoglobulins," <i>J. Molec. Biol.</i> 273:927-948.			
	86.	Arakawa, Y. et al. (November 1990). "Survival Effect of Ciliary Neurotrophic Factor (CNTF) on Chick Embryonic Motoneurons in Culture: Comparison with Other Neurotrophic Factors and Cytokines," <i>J. Neurosci.</i> 10(11):3507-3515.			
	87.	Armour, K.L. et al. (1999). "Recombinant Human IgG Molecules Lacking Fcγ Receptor I Binding and Monocyte Triggering Activities," <i>Eur. J. Immunol.</i> 29:2613-2624.			
	88.	Barbacid, M. (1994). "The Trk Family of Neurotrophin Receptors," <i>J. Neurobiol.</i> 25(11):1386-1403.			
	89.	Barbacid, M. (1995). "Structural and Functional Properties of the TRK Family of Neurotrophin Receptors," <i>Annals New York Acad. Sci.</i> 766:442-458.			
	90.	Barbas, C.F. III et al. (April 1994). "In vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," <i>Proc. Natl. Acad. Sci. USA</i> 91:3809-3813.			
	91.	Belliveau, D.J. et al. (January 27, 1997). "NGF and Neurotrophin-3 Both Activate TrkA on Sympathetic Neurons but Differentially Regulate Survival and Neuriteogenesis," <i>J. Cell Biol.</i> 136(2):375-388.			
	92.	Bibel, M. et al. (December 1, 2000). "Neurotrophins: Key Regulators of Cell Fate and Cell Shape in the Vertebrate Nervous System," <i>Genes Dev.</i> 14(23):2919-2937.			
	93.	Boerner, P. et al. (July 1, 1991). "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes," <i>J. Immunol.</i> 147(1):86-95.			
	94.	Bömmel, H. et al. (November 25, 2002). "Missense Mutation in the <i>Tubulin-Specific Chaperone E (Tbce)</i> Gene in the Mouse Mutant <i>Progressive Motor Neuronopathy</i> , a Model of Human Motoneuron Disease," <i>J. Cell Biol.</i> 159:563-569.			
	95.	Bristol-Meyers Squibb Company (March 2003). "Taxol (paclitaxel) Product Information Sheet and Patient Information" located at < http://www.taxol.com >, six pages.			
	96.	Brown, B.A. et al. (July 1, 1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/549,441	
			Filing Date	(Intl.) March 22, 2004	
			First Named Inventor	David L. SHELTON	
			Art Unit	1644	
			Examiner Name	R. Schwadron	
Sheet	4	of	10	Attorney Docket Number	514712001600

97.	Buchman, V.L. et al. (1993). "Different Neurotrophins are Expressed and Act in a Developmental Sequence to Promote the Survival of Embryonic Sensory Neurons," <i>Development</i> 118:989-1001.	
98.	Buck, D.W. et al. (April 1982). "Monoclonal Antibodies Specific For Cell Culture Mycoplasmas," <i>In Vitro</i> 18(4):377-381.	
99.	Campana, W.M. et al. (April 1998). "Prosaptide Prevents Paclitaxel Neurotoxicity," <i>NeuroToxicology</i> 19(2):237-244.	
100.	Capel, P.J.A. et al. (1994). "Heterogeneity of Human IgG Fc Receptors," <i>Immunomethods</i> 4:25-34.	
101.	Chaplan, S.R. et al. (1994). "Quantitative Assessment of Tactile Allodynia in the Rat Paw," <i>J. Neurosci. Methods</i> 53:55-63.	
102.	Chaudhry, V. et al. (February 2000). "Tolerability of Recombinant-Methionyl Human Neurotrophin-3 (r-metHuNT3) in Healthy Subjects," <i>Muscle and Nerve</i> 23:189-192.	
103.	Chiou, H.C. et al. (1994). "In Vivo Gene Therapy via Receptor-Mediated DNA Delivery," <i>In Gene Therapeutics: Methods and Applications of Direct Gene Transfer</i> , Wolff, J.A., ed., Birkhauser: Boston, MA, pp. 143-156.	
104.	Chothia, C. et al. (December 21/28, 1989). "Conformations of Immunoglobulin Hypervariable Regions," <i>Nature</i> 342:877- 883.	
105.	Clackson, T. et al. (August 15, 1991). "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352:624-628.	
106.	Cliffer, K.D. et al. (January 1998). "Physiological Characterization of Taxol-Induced Large-Fiber Sensory Neuropathy in the Rat," <i>Ann. Neurol.</i> 43(1):46-55.	
107.	Clynes, R. et al. (January 1998). "Fc Receptors Are Required in Passive and Active Immunity to Melanoma," <i>Proc. Natl. Acad. Sci. USA</i> 95:652-656.	
108.	Cole, S.P.C. et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <i>In Monoclonal Antibodies and Cancer Therapy</i> , Reisfeld, R. et al. eds., Alan R. Liss, Inc.: New York, NY, pp.77-96.	
109.	Connelly, S. et al. (February 1995). "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice," <i>Human Gene Therapy</i> 6:185-193.	
110.	Cook, S.A. et al. (March 1995). "Neuromuscular Degeneration (<i>nmd</i>): A Mutation on Mouse Chromosome 19 That Causes Motor Neuron Degeneration," <i>Mamm. Genome</i> 6(3):187-191.	
111.	Coulie, B. et al. (July 2000). "Recombinant Human Neurotrophic Factors Accelerate Colonic Transit and Relieve Constipation in Humans," <i>Gastroenterology</i> 119(1):41-50.	
112.	Cox, G.A. et al. (December 1998). "Identification of the Mouse Neuromuscular Degeneration Gene and Mapping of a Second Site Suppressor Allele," <i>Neuron</i> 21(6):1327-1337.	
113.	Curiel, D.T. et al. (1992). "High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes," <i>Hum. Gene Ther.</i> 3:147-154.	
114.	Daugherty, B.L. et al. (1991). "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.	
115.	Davies, A.M. et al. (October 1993). "p75-Deficient Trigeminal Sensory Neurons Have an Altered Response to NGF but Not to Other Neurotrophins," <i>Neuron</i> 11:565-574.	
116.	Davies, A.M. et al. (November 1993). "Neurotrophin-4/5 is a Mammalian-Specific Survival Factor for Distinct Populations of Sensory Neurons," <i>J. Neurosci.</i> 13(11):4961-4967.	
117.	De Haas, M. et al. (October 1995). "Fcγ Receptors of Phagocytes," <i>J. Lab. Clin. Med.</i> 126:330-341.	
118.	Diener, P.S. et al. (October 3, 1994). "Neurotrophic Factors Prevent the Death of CNS Neurons After Spinal Cord Lesions in Newborn Rats," <i>Neuroreport</i> 5(15):1913-1917.	
119.	Dina, O.A. et al. (2001). "Role of Protein Kinase Cε and Protein Kinase A in a Model of Paclitaxel-Induced Painful Peripheral Neuropathy in the Rat," <i>Neuroscience</i> 108(3):507-515.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/549,441
				Filing Date	(Intl.) March 22, 2004
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	5	of	10	Attorney Docket Number	514712001600

120.	DiStefano, P.S. et al. (May 1992). "The Neurotrophins BDNF, NT-3, and NGF Display Distinct Patterns of Retrograde Axonal Transport in Peripheral and Central Neurons," <i>Neuron</i> 8(5):983-993.	
121.	Duberly, R.M. et al. (May 1, 1997). "Neurotrophin-3-like Immunoreactivity and Trk C Expression in Human Spinal Motoneurons in Amyotrophic Lateral Sclerosis," <i>J. Neurol. Sci.</i> 148(1):33-40.	
122.	Fariñas, I. et al. (August 1998). "Characterization of Neurotrophin and Trk Receptor Functions in Developing Sensory Ganglia: Direct NT-3 Activation of TrkB Neurons In Vivo," <i>Neuron</i> 21:325-334.	
123.	Fernandez-Chacon, R. et al. (April 22, 2004). "The Synaptic Vesicle Protein CSPα Prevents Presynaptic Degeneration," <i>Neuron</i> 42:237-251.	
124.	Findeis, M.A. et al. (May 1993). "Targeted Delivery of DNA for Gene Therapy Via Receptors," <i>Trends Biotechnol.</i> 11:202-205.	
125.	Funakoshi, H. et al. (October 1993). "Differential Expression of mRNAs for Neurotrophins and Their Receptors After Axotomy of the Sciatic Nerve," <i>J. Cell Biol.</i> 123(2):455-465.	
126.	Gazzano-Santoro, H. et al. (1996). "A Non-Radioactive Complement-Dependent Cytotoxicity Assay For Anti-CD20 Monoclonal Antibody," <i>J. Immunol. Methods</i> 202:163-171.	
127.	Griesbeck, O. et al. (September 1, 1995). "Expression of Neurotrophins in Skeletal Muscle: Quantitative Comparison and Significance for Motoneuron Survival and Maintenance of Function," <i>J. Neurosci. Res.</i> 42(1):21-33.	
128.	Griffiths, A.D. et al. (1993). "Human Anti-Self Antibodies with High Specificity From Phage Display Libraries," <i>EMBO J.</i> 12(2):725-734.	
129.	Grohmann, K. et al. (November 1999). "Diaphragmatic Spinal Muscular Atrophy with Respiratory Distress Is Heterogeneous, and One Form Is Linked to Chromosome 11q13-q21," <i>Am. J. Hum. Genet.</i> 65(5):1459-1462.	
130.	Grohmann, K. et al. (September 2001). "Mutations in the Gene Encoding Immunoglobulin μ-Binding Protein 2 Cause Spinal Muscular Atrophy with Respiratory Distress Type 1," <i>Nat. Genet.</i> 29(1):75-77.	
131.	Grohmann, K. et al. (December 2003). "Infantile Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD1)," <i>Ann. Neurol.</i> 54(6):719-724.	
132.	Grohmann, K. et al. (September 15, 2004). "Characterization of Ighmbp2 in Motor Neurons and Implications for the Pathomechanism in a Mouse Model of Human Spinal Muscular Atrophy With Respiratory Distress Type 1 (SMARD1)," <i>Hum. Mol. Genet.</i> 13(18):2031-2042.	
133.	Guyer, R.L. et al. (August 1976). "Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors," <i>J. Immunol.</i> 117(2):587-593.	
134.	Haase, G. et al. (April 1997). "Gene Therapy of Murine Motor Neuron Disease Using Adenoviral Vectors for Neurotrophic Factors," <i>Nat. Med.</i> 3(4):429-436.	
135.	Haase, G. et al. (1998). "Adenovirus-Mediated Transfer of the Neurotrophin-3 Gene Into Skeletal Muscle of pmn Mice: Therapeutic Effects and Mechanisms of Action," <i>J. Neurol. Sci.</i> 160(Suppl. 1):S97-S105.	
136.	Hawkins, R.E. et al. (1992). "Selection of Phage Antibodies by Binding Affinity: Mimicking Affinity Maturation," <i>J. Mol. Biol.</i> 226:889-896.	
137.	Helgren, M.E. et al. (January 1, 1997). "Neurotrophin-3 Administration Attenuates Deficits of Pyridoxine-Induced Large-Fiber Sensory Neuropathy," <i>J. Neurosci.</i> 17(1):372-382.	
138.	Henderson, C.E. et al. (May 20, 1993). "Neurotrophins Promote Motor Neuron Survival and are Present in Embryonic Limb Bud," <i>Nature</i> 363(6426):266-270.	
139.	Henderson, C.E. et al. (November 11, 1994). "GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle," <i>Science</i> 266:1062-1064.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/549,441	
			Filing Date	(Intl.) March 22, 2004	
			First Named Inventor	David L. SHELTON	
			Art Unit	1644	
			Examiner Name	R. Schwadron	
Sheet	6	of	10	Attorney Docket Number	514712001600

140.	Hongo, J. et al. (2001). "Agonist Monoclonal Antibodies to Human trkC Receptor Map to Epitopes Overlapping with NT-3 Binding Site," (31st Annual Meeting, San Diego, CA, November 10-15, 2001) <i>Society for Neuroscience Abstracts</i> 27(1):356 Abstract 137.4.	
141.	Hoogenboom, H.R. et al. (1991). "By-Passing Immunisation: Human Antibodies From Synthetic Repertoires of Germline V _H Gene Segments Rearranged <i>in Vitro</i> ," <i>J. Mol. Biol.</i> 227:381-388.	
142.	Horie, H. et al. (December 30, 1994). "Three-Dimensional Cell Aggregation Enhances Growth-Promoting Activity of NGF in Adult DRG," <i>NeuroReport</i> 6(1):37-40.	
143.	Iliades, P. et al. (1997). "Triabodies: Single Chain Fv Fragments Without a Linker Form Trivalent Trimers," <i>FEBS Letters</i> 409:437-441.	
144.	International Search Report issued for PCT Application No. PCT/US03/41367 filed on December 23, 2003, mailed on December 28, 2004, 4 pages.	
145.	International Search Report issued for PCT Application No. PCT/US04/43435 filed December 23, 2004, mailed on May 8, 2006, three pages.	
146.	International Search Report issued for PCT Application No. PCT/US2004/008865 filed March 22, 2004, mailed on January 7, 2005, four pages.	
147.	International Search Report issued for PCT Application No. PCT/US2006/016046 filed April 26, 2006, mailed on January 17, 2007, six pages.	
148.	Jackson, J.R. et al. (1995). "In Vitro Antibody Maturation: Improvement of a High Affinity, Neutralizing Antibody Against IL-1 β ," <i>J. Immunol.</i> 154(7):3310-3319.	
149.	Johnson, K.S. et al. (1993). "Human Antibody Engineering," <i>Current Opinion in Structural Biology</i> 3:564-571.	
150.	Jolly, D. (1994). "Viral Vector Systems for Gene Therapy," <i>Cancer Gene Therapy</i> 1(1):51-64.	
151.	Jones, P.T. et al. (May 29, 1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," <i>Nature</i> 321:522-525.	
152.	Kabat, E.A. et al. (1991). <i>Sequences of Proteins of Immunological Interest</i> , Fifth Edition, National Institutes of Health: Bethesda, MD pp. iii-xi (Table of Contents Only.)	
153.	Kang, H. et al. (March 17, 1995). "Long-Lasting Neurotrophin-Induced Enhancement of Synaptic Transmission in the Adult Hippocampus," <i>Science</i> 267:1658-1662.	
154.	Kapli, M.G. et al. (October 1994). "Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain," <i>Nature Genetics</i> 8:148-153.	
155.	Karlsson, R. et al. (1994). "Kinetic and Concentration Analysis Using BIA Technology" <i>Methods: A Companion to Methods in Enzymology</i> , Academic Press, Inc., 6:99-110.	
156.	Kim, J-K. et al. (October 1994). "Localization of the Site of the Murine IgG1 Molecule that is Involved in Binding to the Murine Intestinal Fc Receptor," <i>Eur. J. Immunol.</i> 24(10):2429-2434.	
157.	Kimura, O. et al. (1994). "Retroviral Delivery of DNA into the Livers of Transgenic Mice Bearing Premalignant and Malignant Hepatocellular Carcinomas," <i>Human Gene Therapy</i> 5:845-852.	
158.	Knusel, B. et al. (1997). "Ligand-Induced Down-Regulation of TRK Messenger RNA, Protein and Tyrosine Phosphorylation in Rat Cortical Neurons," <i>Neuroscience</i> 78(3):851-862.	
159.	Kohler, B. et al. (August 7, 1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.	
160.	Koliatsos, V.E. et al. (March 1993). "Evidence That Brain-Derived Neurotrophic Factor Is a Trophic Factor for Motor Neurons In Vivo," <i>Neuron</i> 10(3):359-367.	
161.	Kortt, A.A. et al. (1997). "Single-Chain Fv Fragments of Anti-Neuraminidase Antibody NC10 Containing Five- and Ten-Residue Linkers Form Dimers and With Zero-Residue Linker a Trimer," <i>Protein Engineering</i> 10(4):423-433.	
162.	Lefebvre, S. et al. (January 13, 1995). "Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene," <i>Cell</i> 80(1):155-165.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/549,441		
		Filing Date	(Intl.) March 22, 2004		
		First Named Inventor	David L. SHELTON		
		Art Unit	1644		
		Examiner Name	R. Schwadron		
Sheet	7	of	10	Attorney Docket Number	514712001600

163.	Lindsay, R.M. (July 1988). "Nerve Growth Factors (NGF, BDNF) Enhance Axonal Regeneration But Are Not Required For Survival of Adult Sensory Neurons," <i>J. Neurosci.</i> 8(7):2394-2405.
164.	Liou, J-C. et al. (April 1, 1997). "Regulation of Quantal Secretion from Developing Motoneurons by Postsynaptic Activity-Dependent Release of NT-3," <i>J. Neurosci.</i> 17(7):2459-2468.
165.	LoBuglio, A.F. et al. (June 1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>Proc. Natl. Acad. Sci. USA</i> 86:4220-4224.
166.	Loeb, J.A. et al. (February 15, 1997). "Neurotrophic Factors Increase Neuregulin Expression in Embryonic Ventral Spinal Cord Neurons," <i>J. Neurosci.</i> 17(4):1416-1424.
167.	Loeb, J.A. et al. (March 15, 2002). "Neuregulin Expression at Neuromuscular Synapses Is Modulated by Synaptic Activity and Neurotrophic Factors," <i>J. Neurosci.</i> 22(6):2206-2214.
168.	Lohof, A.M. (May 27, 1993). "Potentiation of Developing Neuromuscular Synapses by the Neurotrophins NT-3 and BDNF," <i>Nature</i> 363(6427):350-353.
169.	Lonberg, N. et al. (1995). "Human Antibodies From Transgenic Mice," <i>Int. Rev. Immunol.</i> 13:65-93.
170.	Maddatu, T.P. et al. (June 1, 2004). "Transgenic Rescue of Neurogenic Atrophy in the <i>nmd</i> Mouse Reveals a Role for <i>Ighmbp2</i> in Dilated Cardiomyopathy," <i>Hum. Mol. Genet.</i> 13(11):1105-1115.
171.	Mahato, R.I. et al. (1997). "Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm Res.</i> 14(7):853-859.
172.	Marks, J.D. et al. (1991). "By-Passing Immunization: Human Antibodies From V-Gene Libraries Displayed on Phage," <i>J. Mol. Biol.</i> 222:581-597.
173.	Marks, J.D. et al. (July 1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technol.</i> 10:779-783.
174.	McCafferty, J. et al. (December 6, 1990). "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," <i>Nature</i> 348:552-553.
175.	McComas, A.J. (July 1991). "Invited Review: Motor Unit Estimation: Methods, Results, and Present Status," <i>Muscle Nerve</i> 14(7):585-597.
176.	Mercuri, E. et al. (February 2004). "Pilot Trial of Phenylbutyrate in Spinal Muscular Atrophy," <i>Neuromuscul. Disord.</i> 14(2):130-135.
177.	Michaud, L.B. et al. (November 2000). "Risks and Benefits of Taxanes in Breast and Ovarian Cancer," <i>Drug Safety</i> 23(5):401-428.
178.	Miller, R.G. et al. (February 1996). "A Placebo-Controlled Trial of Recombinant Human Ciliary Neurotrophic (rhCNTF) Factor in Amyotrophic Lateral Sclerosis," <i>Ann. Neurol.</i> 39(2):256-260.
179.	Milstein, C. et al. (October 1983). "Hybrid Hydridomas and Their Use in Immunohistochemistry," <i>Nature</i> 305:537-539.
180.	Mitsumoto, H. et al. (August 19, 1994). "Arrest of Motor Neuron Disease in <i>wobbler</i> Mice Cotreated with CNTF and BDNF," <i>Science</i> 265:1107-1110.
181.	Morrison, S.L. et al. (November 1984). "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains," <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855.
182.	Oppenheim, R.W. (August 1996). "Neurotrophic Survival Molecules for Motoneurons: An Embarrassment of Riches," <i>Neuron</i> 17:195-197.
183.	Peeters, K. et al. (2001). "Production of Antibodies and Antibody Fragments in Plants," <i>Vaccine</i> 19:2756-2761.
184.	Philip, R. et al. (April 1994). "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Mol. Cell Biol.</i> 14(4):2411-2418.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/549,441
				Filing Date	(Intl.) March 22, 2004
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	8	of	10	Attorney Docket Number	514712001600

185.	Pitt, M. et al. (December 2003). "Severe Infantile Neuropathy with Diaphragmatic Weakness and Its Relationship to SMARD1," <i>Brain</i> 126(12):2682-2692.	
186.	Poduslo, J.F. et al. (1996). "Permeability at the Blood-Brain and Blood-Nerve Barriers of the Neurotrophic Factors: NGF, CNTF, NT-3, BDNF," <i>Brain Res. Mol. Brain Res.</i> 36(2):280-286.	
187.	Pollock, D.P. et al. (1999). "Transgenic Milk as a Method For the Production of Recombinant Antibodies," <i>J. Immunol. Methods</i> 231:147-157.	
188.	Polomano, R.C. et al. (March 2001). "Chemotherapy-evoked Painful Peripheral Neuropathy," <i>Pain Medicine</i> 2(1):8-14.	
189.	Polomano, R.C. et al. (2001). "A Painful Peripheral Neuropathy in the Rat Produced by the Chemotherapeutic Drug, Paclitaxel," <i>Pain</i> 94(3):293-304.	
190.	Poo, M-M. (January 2001). "Neurotrophins as Synaptic Modulators," <i>Nat. Rev. Neurosci.</i> 2(1):24-32.	
191.	Poulsen, K. et al. (2001). "Agonist Monoclonal Antibodies to trkC Receptor for Treating Large Fiber Sensory Neuropathy: Improved Drug Candidates over NT-3," (31st Annual Meeting, San Diego, CA, November 10-15, 2001), <i>Society for Neuroscience Abstracts</i> 27(1):356 Abstract No. 137.5.	
192.	Quasthoff, S. et al. (2002). "Chemotherapy-Induced Peripheral Neuropathy," <i>J. Neurol.</i> 249:9-17.	
193.	Ravetch, J.V. et al. (1991). "Fc Receptors," <i>Ann. Rev. Immunol.</i> 9:457-492.	
194.	Riechmann, L. et al. (March 24, 1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327.	
195.	Rogers, S.D. et al. (May 1997). "Expression of Endothelin-B Receptors by Glia <i>in Vivo</i> is Increased After CNS Injury in Rats, Rabbits, and Humans," <i>Exp. Neurol.</i> 145(1):180-195.	
196.	Ruiz, R. et al. (July 1, 2005). "Treatment with trkC Agonist Antibodies Delays Disease Progression in Neuromuscular Degeneration (<i>nmd</i>) Mice," <i>Human Molecular Genetics</i> 14(13):1825-1837.	
197.	Rydén, M. et al. (March 8, 1996). "Binding of Neurotrophin-3 to p75 ^{LNGFR} , TrkA, and TrkB Mediated by a Single Functional Epitope Distinct From That Recognized by TrkC," <i>J. Biol. Chem.</i> 271(10):5623-5627.	
198.	Sadick, M.D. et al. (August 1, 1997). "Analysis of Neurotrophin/Receptor Interactions with a gD-Flag-Modified Quantitative Kinase Receptor Activation (gD.KIRA) Enzyme-Linked Immunosorbent Assay," <i>Experimental Cell Research</i> 234(2):354-361.	
199.	Sagot, Y. et al. (June 1, 1995). "Polymer Encapsulated Cell Lines Genetically Engineered to Release Ciliary Neurotrophic Factor Can Slow Down Progressive Motor Neuronopathy in the Mouse," <i>Eur. J. Neurosci.</i> 7(6):1313-1322.	
200.	Sagot, Y. et al. (September 1997). "Clinical and Molecular Aspects of Motoneuron Diseases: Animal Models, Neurotrophic Factors and Bcl-2 Oncoprotein," <i>Trends Pharmacol. Sci.</i> 18(9):330-337.	
201.	Sagot, Y. et al. (February 1, 1998). "Differential Effects of Neurotrophic Factors on Motoneuron Retrograde Labeling in a Murine Model of Motoneuron Disease," <i>J. Neurosci.</i> 18(3):1132-1141.	
202.	Schier, R. et al. (1995). "Identification of Functional and Structural Amino-Acid Residues by Parsimonious Mutagenesis," <i>Gene</i> 169:147-155.	
203.	Sendtner, M. et al. (May 31, 1990). "Ciliary Neurotrophic Factor Prevents the Degeneration of Motor Neurons After Axotomy," <i>Nature</i> 345(6274):440-441.	
204.	Sendtner, M. et al. (August 2, 1992). "Ciliary Neurotrophic Factor Prevents the Degeneration of Motor Neurons in Mouse Mutant Progressive Motor Neuronopathy," <i>Nature</i> 358(6386):502-504.	
205.	Sendtner, M. (April 1997). "Gene Therapy for Motor Neuron Disease," <i>Nat. Med.</i> 3(4):380-381.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/549,441
				Filing Date	(Intl.) March 22, 2004
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	9	of	10	Attorney Docket Number	514712001600

206.	Sendtner, M. (March 1998). "Neurotrophic Factors: Effects in Modulating Properties of the Neuromuscular Endplate," <i>Cytokine Growth Factor Rev.</i> 9(1):1-7.	
207.	Sevarino, K.A. et al. (January 15, 1988). "Biosynthesis of Thyrotropin-Releasing Hormone by a Rat Medullary Thyroid Carcinoma Cell Line," <i>J. Biol. Chem.</i> 263(2):620-623.	
208.	Shaw, D.R. et al. (June 15, 1987). "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) To A Colon Cancer Tumor-Associated Antigen," <i>J. Immunol.</i> 138(12):4534-4538.	
209.	Sheets, M.D. et al. (May 1998). "Efficient Construction of a Large Nonimmune Phage Antibody Library: The Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens," <i>Proc. Natl. Acad. Sci. USA</i> 95:6157-6162.	
210.	Shelfner, J.M. et al. (2001). "Motor Unit Number Estimation in Neurologic Disease" Chapter 3 <i>In Advances in Neurology</i> , Pourmand, R. et al. eds., Lippincott, Williams & Wilkins: Philadelphia, PA, 88:33-52.	
211.	Shelton, D.L. et al. (January 1995). "Human trks: Molecular Cloning, Tissue Distribution, and Expression of Extracellular Domain Immuno adhesins," <i>J. Neurosci.</i> 15(1):477-491.	
212.	Supplementary European Search Report mailed July 4, 2006, for EP Application No. 03814397.0 filed December 3, 2003, four pages.	
213.	Supplementary European Search Report mailed March 6, 2007, for EP Application No. 04758063.4 filed March 22, 2004, four pages.	
214.	Suresh, M.R. et al. (1986). "Bispecific Monoclonal Antibodies From Hybrid Hybridomas" Chapter 17 <i>In Methods in Enzymology</i> , Academic Press, Inc., 121:210-229.	
215.	Thoenen, H. et al. (November 2002). "Neurotrophins: From Enthusiastic Expectations Through Sobering Experiences to Rational Therapeutic Approaches," <i>Nat. Neurosci.</i> 5(Suppl.):1046-1050.	
216.	Tsoufas, P. et al. (May 1993). "The Rat <i>trkC</i> Locus Encodes Multiple Neurogenic Receptors That Exhibit Differential Response to Neurotrophin-3 in PC12 Cells," <i>Neuron</i> 10:975-990.	
217.	Urfer, R. et al. (1997). "Specificity Determinants in Neurotrophin-3 and Design of Nerve Growth Factor-Based <i>trkC</i> Agonists by Changing Central β -Strand Bundle Residues to Their Neurotrophin-3 Analogs," <i>Biochem.</i> 36(16):4775-4781.	
218.	Urfer, R. et al. (March 6, 1998). "High Resolution Mapping of the Binding Site of TrkA for Nerve Growth Factor and TrkC for Neurotrophin-3 on the Second Immunoglobulin-like Domain of the Trk Receptors," <i>J. Biol. Chem.</i> 273(10):5829-5840.	
219.	Vahdat, L.T. et al. (2002). "Breast Cancer: Phase II Trial of Sequential High-Dose Chemotherapy With Paclitaxel, Melphalan and Cyclophosphamide, Thiotepa and Carboplatin with Peripheral Blood Progenitor Support in Women with Responding Metastatic Breast Cancer," <i>Bone Marrow Transplantation</i> 30:149-153.	
220.	Vaughan, T.J. et al. (March 1996). "Human Antibodies with Sub-Nanomolar Affinities Isolated from a Large Non-Immunized Phage Display Library," <i>Nature Biotechnology</i> 14:309-314.	
221.	Vejsada, R. et al. (January 1, 1995). "Quantitative Comparison of the Transient Rescue Effects of Neurotrophic Factors on Axotomized Motoneurons in Vivo," <i>Eur. J. Neurosci.</i> 7(1):108-115.	
222.	Verhoeyen, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536.	
223.	Wang, T. et al. (July 1995). "Neurotrophins Promote Maturation of Developing Neuromuscular Synapses," <i>J. Neurosci.</i> 15(7):4796-4805.	
224.	Waterhouse, P. et al. (1993). "Combinatorial Infection and <i>in vivo</i> Recombination: A Strategy for Making Large Phage Antibody Repertoires," <i>Nucl. Acids Res.</i> 21(9):2265-2266.	
225.	Winter, G. et al. (January 24, 1991). "Man-Made Antibodies," <i>Nature</i> 349:293-299.	
226.	Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," <i>Annu. Rev. Immunol.</i> 12:433-455.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/549,441
				Filing Date	(Intl.) March 22, 2004
				First Named Inventor	David L. SHELTON
				Art Unit	1644
				Examiner Name	R. Schwadron
Sheet	10	of	10	Attorney Docket Number	514712001600

227.	Wirth, B. (2000). "An Update of the Mutation Spectrum of the Survival Motor Neuron Gene (SMN1) in Autosomal Recessive Spinal Muscular Atrophy (SMA)," <i>Hum. Mutat.</i> 15:228-237.	
228.	Woffendin, C. et al. (November 1994). "Nonviral and Viral Delivery of a Human Immunodeficiency Virus Protective Gene into Primary Human T Cells," <i>Proc. Natl. Acad. Sci. USA</i> 91:11581-11585.	
229.	Wu, C.H. et al. (October 15, 1989). "Targeting Genes: Delivery and Persistent Expression of a Foreign Gene Driven by Mammalian Regulatory Elements <i>in Vivo</i> ," <i>J. Biol. Chem.</i> 264(29):16985-16987.	
230.	Wu, G.Y. et al. (August 5, 1991). "Receptor-Mediated Gene Delivery <i>in Vivo</i> : Partial Correction of Genetic Analbuminemia in Nagase Rats," <i>J. Biol. Chem.</i> 266(22):14338-14342.	
231.	Wu, G.Y. et al. (April 15, 1994). "Incorporation of Adenovirus into a Ligand-Based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression," <i>J. Biol. Chem.</i> 269(15):11542-11546.	
232.	Yan, Q. et al. (December 24-31, 1992). "Brain-Derived Neurotrophic Factor Rescues Spinal Motor Neurons from Axotomy-Induced Cell Death," <i>Nature</i> 360(6406):753-755.	
233.	Yan, Q. et al. (December 1993). "Influences of Neurotrophins on Mammalian Motoneurons <i>in vivo</i> ," <i>J. Neurobiol.</i> 24(12):1555-1577.	
234.	Yelton, D.E. et al. (1995). "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis," <i>J. Immunol.</i> 155:1994-2004.	
235.	Zenke, M. et al. (May 1990). "Receptor-Mediated Endocytosis of Transferrin-Polycation Conjugates: An Efficient Way to Introduce DNA Into Hematopoietic Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87:3655-3659.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--